12,372 trials
Chronic Obstructive Pulmonary Diseases · Chronic Airways Limitation · Bronchitis
Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Primary: Decrease in the NIH-CPSI Total Score by at Least 6 Points — 103; 38 Participants
Metabolic Syndrome
Primary: Change in Fasting Unscaled Flow Mediated Dilation (FMD) of the Brachial Artery — -0.45; 0.76; 3.50; 5.28 Percent change in diameters — p=0.045
Carcinoma, Hepatocellular
Primary: Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage — 17; 3…
Diabetes Mellitus, Type 2
Primary: Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV)…
CNS Lesion · Blood Brain Barrier Defect
Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.90; 2.08; 3.64; 1.74 mean of a score (on a scale) per patient — p=<.0001
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number and Percentage of Participants With Serious Adverse Events — 15; 12; 265; 266 Participants
Cancer Colon
Primary: The Feasibility of Running the Study, to See if it Could be Run as a Large Multi-centre Study — 16; 18 participants
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] — 2.70; -29.94 percent change from baseline — p=<.0001
Autism · Autism Spectrum Disorder · ASD
Primary: Change From Baseline in Parent Rated Social Responsiveness Scale, Second Edition (SRS-2) Total Scores During Treatment. — 81.3690; 79.6795; 82.2281; -5.6779 T-score
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
Single Ventricle Heart Disease
Primary: Effect of Udenafil 87.5 mg BID Treatment on Liver Stiffness in Udenafil Continuation and Naive Groups After 52 Weeks, as Determined by Ultrasound Shear Wave Elastography…
Eosinophilic Gastroenteritis
Primary: Change From Baseline in Mean Number of Peak Eosinophils (Eos) Count Per High-power Field (Hpf) in Gastrointestinal (GI) Biopsies — -100.4; 122.8 Peak # of eosinophils…
COVID-19
Primary: Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs) — 2; 1; 1; 0 Participants
Schizophrenia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 466 Participants